eribulin mesylate
SpainDrugs containing this active substance
-
It is used to treat adult patients with locally advanced or metastatic breast cancer, or with advanced or metastatic liposarcoma, provided that another treatment that previously worked has ceased to be effective.
Form: solution for injection
Active substance Dosage eribulin mesylate 0,5 mg/ml Manufacturer: Advanz Pharma Limited
-
It is used in adults to treat locally advanced or metastatic breast cancer, and also for the treatment of advanced or metastatic liposarcoma, provided that another treatment previously used has ceased to be effective.
Form: solution for injection
Active substance Dosage eribulin mesylate 1 mg Manufacturer: Baxter Holding B.V.
-
It is used to treat adult patients with locally advanced or metastatic breast cancer, or with advanced or metastatic liposarcoma, when previous treatments have stopped working.
Form: solution for injection
Active substance Dosage eribulin mesylate 0,5 mg/ml Manufacturer: Glenmark Arzneimittel Gmbh
-
It is used to treat adult patients with locally advanced or metastatic breast cancer, as well as for the treatment of advanced or metastatic liposarcoma, provided that another treatment that was previously effective has ceased to work.
Form: solution for injection
Active substance Dosage eribulin mesylate 0,5 mg Manufacturer: Laboratorio Stada S.L.
-
It is used in adults to treat locally advanced or metastatic breast cancer, and also for the treatment of advanced or metastatic liposarcoma, provided that another treatment that was previously effective has been used.
Form: solution for injection
Active substance Dosage eribulin mesylate 0,5 mg/ml Manufacturer: Zentiva K.S.
-
It is used to treat adult patients with locally advanced or metastatic breast cancer, as well as for the treatment of adult patients with advanced or metastatic liposarcoma, provided that another treatment previously used has ceased to be effective.
Form: solution for injection
Active substance Dosage eribulin mesylate 0,44 mg Manufacturer: Eisai Gmbh